News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lombard Medical Technologies Appoints Raymond W. Cohen as Chairman


7/10/2013 9:31:51 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

London, UK, 10 July 2013 – Lombard Medical Technologies PLC (AIM:LMT), the specialist medical technology company focussed on innovative vascular products, is pleased to announce the appointment of Raymond Wayne Cohen as Non-executive Chairman, with immediate effect.

Mr. Cohen, a US national and aged 54, has extensive international medical device experience having held several Chairman and CEO positions on the boards of both publicly listed and private life sciences companies in the US and Europe. He is currently Non-executive Chairman of Jenavalve Technology, Inc., a Munich-based developer, manufacturer and marketer of transcatheter aortic valve systems; Non-executive Chairman of Syncroness, Inc., a contract engineering firm; a Non-executive Director of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a developer and marketer of oncology and haematology drugs; a Non-executive Director of BioLife Solutions, Inc. (OTC:BLFS), a manufacturer of biopreservation media for human cells; and a Non-executive Director of LoneStar Heart, Inc., a developer of biomaterials for the treatment of congestive heart failure.

From mid-2010 to late 2012, Mr. Cohen served as Chief Executive Officer of Vessix Vascular, Inc., a developer of a novel percutaneous radiofrequency balloon catheter renal denervation system used to treat uncontrolled hypertension. In November 2012, during his tenure as CEO, the company was acquired by Boston Scientific Corporation (NYSE:BSX) in a structured transaction valued at up to $425 million.

As announced in April, John Rush decided to step down as Non-executive Chairman following the achievement of FDA approval for Aorfix™ in the United States. John Rush remains an active and committed member of the Board as a Non-executive Director.

CEO of Lombard Medical, Simon Hubbert, commented:

“The Board is delighted to appoint a Chairman of Raymond’s calibre and experience. He brings with him extensive knowledge of the medical device sector in the US and international markets, which will serve the Company well as it executes its strategy. We also thank John for his leadership over the last few years and are pleased he will remain with the Company as a valued member of the Board.”

There is no further information to be disclosed in accordance with Schedule Two paragraph (g) of the AIM Rules, save as set out below:

Directorships in the last 5 years:

Jenavalve Technology, Inc*

Syncroness, Inc.*

Spectrum Pharmaceuticals, Inc.*

BioLife Solutions, Inc.*

LoneStar Heart, Inc.*

Cardiogenesis Corp.

Vessix Vascular, Inc.

CardioPolymers, Inc.

Cardiac Science, Inc.

Cardiac Science Corp.

* Current directorship

For further information:

Lombard Medical Technologies PLC Tel: 01235 750 800

Simon Hubbert, Chief Executive Officer

Ian Ardill, Chief Financial Officer

Canaccord Genuity Limited

Lucy Tilley / Tim Redfern / Henry Fitzgerald O’Connor / Dr Julian Feneley Tel: 020 7523 8000

FTI Consulting

Simon Conway / Susan Stuart / Victoria Foster Mitchell Tel: 020 7831 3113

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1.2 billion dollar per annum abdominal aortic aneurysm (AAA) repair market. AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015. The Company’s lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease. Aorfix™ is currently being commercialised in the EU, and has been approved by the FDA in the US, the first AAA stent graft not of US origin to gain FDA approval. The Company intends to launch AorfixTM with AorflexTM in the US in H2 2013; a coordinated launch event will take place at the VEITH symposium in New York City in November 2013.

The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA.

Further background on the Company can be found at www.lombardmedical.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES